A New Treatment of Retinitis Pigmentosa

Status Not yet recruiting

Clinical Trial Summary

This study is designed to assess and to evaluate the therapeutic effect of retrobulbar injection of autoserum in the treatment of retinitis pigmentosa.

Clinical Trial Description

The retinitis pigmentosa(RP) is an hereditary disease which causes visual deficiency leading to blindness. The methods of treatment include gene therapy, stem cell therapy and visual prothesis, etc. But all these methods own limitations can not be conquered in a short period. It was proved that vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) decreased in the aqueous humor of patients of RP. But the traditional exogenous nerve growth factors (NGFs) were immunogenic proteins and may cause inflammation. Autoserum contain a large amount of active factors and will not cause exclusive reaction. In this study we aim to assess and to evaluate the therapeutic effect and the safety of retrobulbar injection of autoserum in the treatment of retinitis pigmentosa. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03998384
Study type	Interventional
Source	Aier School of Ophthalmology, Central South University
Contact	Hongxia Wang, MD
Phone	18302183233
Email	whxeye@163.com
Status	Not yet recruiting
Phase	N/A
Start date	January 1, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01432847` - Cell Collection to Study Eye Diseases
Completed	`NCT04983914` - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting	`NCT03845218` - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed	`NCT00231010` - Molecular Genetics of Retinal Degenerations
Active, not recruiting	`NCT04611503` - PDE6A Gene Therapy for Retinitis Pigmentosa	Phase 1/Phase 2
Completed	`NCT02909985` - Visual Activity Evoked by Infrared in Humans After Dark Adaptation	N/A
Recruiting	`NCT01914913` - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa	Phase 1/Phase 2
Completed	`NCT01949623` - Biomarkers In Retinitis Pigmentosa (BIRP)	N/A
Completed	`NCT01835002` - Transcorneal Electrical Stimulation - Multicenter Safety Study	N/A
Completed	`NCT00407602` - Argus® II Retinal Stimulation System Feasibility Protocol	N/A
Completed	`NCT00515814` - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors	N/A
Completed	`NCT00100230` - DHA and X-Linked Retinitis Pigmentosa	Phase 2
Active, not recruiting	`NCT00378742` - Repository for Inherited Eye Diseases
Terminated	`NCT05085964` - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa	Phase 2
Recruiting	`NCT05805007` - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa	Early Phase 1
Not yet recruiting	`NCT06242379` - Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa	Phase 1/Phase 2
Recruiting	`NCT06291935` - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene	Phase 1
Recruiting	`NCT05909488` - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II	Phase 2/Phase 3
Recruiting	`NCT03078309` - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients	Early Phase 1
Completed	`NCT04238858` - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa	N/A